IBM Corp is nearing deal to acquire software company Red Hat Inc in a deal that could exceed $30 billion and allow it to expand its cyber security offerings, people familiar with the matter said on Sunday.
Source:: Reuters – Business News
Newswire
- [ March 6, 2025 ] Plus Therapeutics (NASDAQ: PSTV) Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer Newsmakers
- [ March 3, 2025 ] BioXcel Therapeutics (NASDAQ: BTAI) Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia Newsmakers
- [ February 24, 2025 ] PepGen (NASDAQ: PEPG) Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights Newsmakers
- [ February 18, 2025 ] ScanTech AI (NASDAQ: STAI) Announces Initiative to Combat Contraband in Correctional Facilities Across the Americas Newsmakers
- [ February 18, 2025 ] ProPhase Labs (NASDAQ: PRPH) hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports Newsmakers
- [ February 5, 2025 ] Cumberland Pharmaceuticals (NASDAQ: CPIX) Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease Newsmakers
- [ February 5, 2025 ] Pasithea Therapeutics (NASDAQ: KTTA) Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer Newsmakers
- [ January 30, 2025 ] BigBear.ai (NYSE: BBAI)Awarded Prime IDIQ Contract for U.S. Department of Navy’s SeaPort Next Generation (NxG) Newsmakers
- [ January 30, 2025 ] ScanTech AI Systems (NASDAQ: STAI) Deploys Its Advanced AI-Driven Security Screening Technology to Protect Multiple Nuclear Power Plants Operated by Ontario Power Generation Newsmakers
- [ January 30, 2025 ] Kazia Therapeutics (NASDAQ: KZIA) announces launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer Newsmakers
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.